Short answer
Tvardi Therapeutics, Inc. (TVRD) filed its Q2 2026 10-Q quarterly report on Aug 14, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$6M
- −1176.1% YoY · +5.1% QoQ
- EPS (diluted)
- −$0.68
- −157.6% YoY · +6.8% QoQ
Source: XBRL data from the Tvardi Therapeutics, Inc. (TVRD) Q2 2026 10-Q on SEC EDGAR. USD.
Tvardi Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product revenue since inception
- Net loss $6.5M vs net income $4.2M YoY
- TTI-109 largest R&D focus; TTI-101 HCC trial also incurred costs
- Cash and equivalents $15.8M at June 30, 2026; accumulated deficit $123.7M
- Topline TTI-101 HCC data expected Q4 2026; additional funding required with going-concern doubt
Risk Factors
- Risk Factors section not provided; no new or changed risks identifiable from supplied text
- Capital on Demand™ Sales Agreement dated May 1, 2026, indicating potential equity-financing dilution
- No director or officer Rule 10b5-1 trading arrangements adopted or terminated during the quarter
- No defaults upon senior securities reported
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tvardi Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.